European Commission says no to drug-type pre-market evaluation for devices but authority role foreseen
This article was originally published in RAJ Devices
The European Commission has said that transferring responsibility in the EU for assessing the safety and performance of medical devices from notified bodies to a regulatory authority and centralised authorisation as it exists in the pharmaceutical domain is, for the time being at least, "neither a feasible nor a desirable option".
You may also be interested in...
Where are the biggest challenges for notified bodies and manufacturers now there is some experience with the MDR, and can the sector manage the new regulatory requirements successfully?
The European Commission has finally published detailed guidance on the EU IVDR’s classification rules. The IVDR’s completely new classification regime means guidance is urgently needed.
Do you know how to avoid the pitfalls when it comes to clinical evidence under the MDR? Or whether evidence gathered outside the US counts? Amie Smirthwaite of Maetrics answers these and other pivotal questions in this third and final part of an interview series with Medtech Insight.